# Serum Institute of India

> Indian biotechnological company, vaccine manufacturer

**Wikidata**: [Q3480001](https://www.wikidata.org/wiki/Q3480001)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/Serum_Institute_of_India)  
**Source**: https://4ort.xyz/entity/serum-institute-of-india

## Summary
Serum Institute of India (alias: SII) is an Indian biotechnological company and vaccine manufacturer headquartered in Pune, India. Founded in 1966, it operates in the biotechnology industry and is led at the executive level by CEO Adar Poonawalla, with Cyrus S. Poonawalla identified as a key person.

## Key Facts
- Serum Institute of India is an Indian biotechnological company and vaccine manufacturer.  
- Alias: SII.  
- Official website: http://www.seruminstitute.com/.  
- Inception (founding) date: 1966-01-01.  
- Location / headquarters: Pune, Maharashtra, India.  
- Country of origin: India.  
- Industry classification: biotechnology industry — a science-based sector using living organisms and molecular biology to create products and processes. (biotechnology industry sitelink_count: 2)  
- Organizational class: business — an organization undertaking commercial, industrial, or professional activity. (business [class] sitelink_count: 138)  
- Sitlink count for the entity entry: 26.  
- Wikipedia title: Serum Institute of India.  
- Wikidata description: Indian biotechnological company, vaccine manufacturer.  
- Key person: Cyrus S. Poonawalla — identified as an Indian businessman. (Cyrus S. Poonawalla sitelink_count: 12)  
- Affiliated / leadership: Adar Poonawalla — identified as the CEO of Serum Institute of India. (Adar Poonawalla sitelink_count: 11)  
- Related vaccine (context): AZD1222 — a viral vector vaccine for prevention of COVID-19. (AZD1222 sitelink_count: 54)  
- Created / developed (listed as developed by Serum Institute of India): NVX‑CoV2373 — a vaccine against COVID-19. (NVX‑CoV2373 sitelink_count: 25)  
- Created / developed (listed as developed by Serum Institute of India): MMR vaccine — any of several combined vaccines against measles, mumps, and rubella (inception +1971; MMR vaccine sitelink_count: 41).  
- Location entity metadata: Pune (metropolis in Maharashtra, India) — inception value listed as 1436; Pune sitelink_count: 127.  
- Country metadata: India — inception 1947-08-15; India sitelink_count: 395.

## FAQs
Q: What is Serum Institute of India?  
A: Serum Institute of India (SII) is an Indian biotechnology company that manufactures vaccines. It is described in Wikidata as an Indian biotechnological company and vaccine manufacturer.

Q: Where is Serum Institute of India located?  
A: The company is based in Pune, a metropolis in Maharashtra, India, and its country of origin is India.

Q: When was Serum Institute of India founded?  
A: Serum Institute of India’s inception (founding) date is listed as 1966-01-01.

Q: Who are the key people associated with Serum Institute of India?  
A: Cyrus S. Poonawalla is identified as a key person (an Indian businessman). Adar Poonawalla is identified as the company’s CEO.

Q: Which vaccines are associated with Serum Institute of India?  
A: Items listed as developed by Serum Institute include NVX‑CoV2373 (a vaccine against COVID-19) and the MMR vaccine (combined measles, mumps, rubella vaccines). The company is also related to AZD1222, a viral vector vaccine for prevention of COVID-19.

Q: What industry and organizational class does Serum Institute of India belong to?  
A: Serum Institute operates in the biotechnology industry and is classified as a business — an organization undertaking commercial, industrial, or professional activity.

Q: How can I find official information from Serum Institute of India?  
A: The company’s official website is http://www.seruminstitute.com/.

## Why It Matters
Serum Institute of India matters because it is a dedicated biotechnological company that manufactures vaccines and is explicitly linked to multiple vaccine products and candidates. As an organization founded in 1966 and based in Pune, it is a component of India’s biotech sector and contributes to the development and production of immunization tools such as NVX‑CoV2373 and MMR vaccines. The presence of named leadership (Adar Poonawalla as CEO and Cyrus S. Poonawalla as a key person) indicates an identifiable executive structure guiding its commercial and scientific activities. Its classification as a business in the biotechnology industry situates it at the intersection of commercial production and life-science innovation, addressing needs for vaccine development and supply.

## Notable For
- Being an Indian biotechnological company explicitly identified as a vaccine manufacturer.  
- Having inception in 1966, marking several decades of operation in biotechnology.  
- Developing or being listed as developer for NVX‑CoV2373 (a COVID-19 vaccine candidate).  
- Being listed as developer for MMR vaccines (combined vaccines against measles, mumps, and rubella).  
- A relationship to AZD1222, noted as a viral vector vaccine for prevention of COVID-19.  
- Headquarters located in Pune, Maharashtra, India.  
- Publicly accessible official website: http://www.seruminstitute.com/.  
- Recognized leadership including Adar Poonawalla (CEO) and Cyrus S. Poonawalla (key person).

## Body

### Overview
Serum Institute of India (SII) is described as an Indian biotechnological company and vaccine manufacturer. The entity is officially titled "Serum Institute of India" in Wikipedia/Wikidata metadata and carries the alias "SII". Its website is http://www.seruminstitute.com/.

### Classification and Industry
- Organizational class: business — defined here as an organization undertaking commercial, industrial, or professional activity.  
- Industry: biotechnology industry — described as a science-based sector that uses living organisms and molecular biology to create products and processes. These classifications position SII within the commercial biotechnology sector.

### Location and Origin
- Headquarters: Pune, a metropolis in Maharashtra, India.  
- Country: India.  
- The company’s inception date is recorded as January 1, 1966.  
- Metadata for location: Pune has an inception value listed (1436) and a sitelink_count of 127; India has an inception date of 1947-08-15 and a sitelink_count of 395.

### Leadership and Key People
- Cyrus S. Poonawalla is listed as a key person and described as an Indian businessman. The available metadata lists a sitelink_count of 12 for Cyrus S. Poonawalla.  
- Adar Poonawalla is identified as CEO of Serum Institute of India and has a sitelink_count of 11. This identifies the company leadership structure by name and role.

### Products, Development, and Related Vaccines
- NVX‑CoV2373: Listed as a vaccine against COVID-19 and identified as created/developed by Serum Institute of India. NVX‑CoV2373 has a sitelink_count of 25.  
- MMR vaccine: Listed as created/developed by Serum Institute; described as any of several combined vaccines against measles, mumps, and rubella. The MMR vaccine entry has an inception marker (+1971) and a sitelink_count of 41.  
- AZD1222: Listed as a related item; described as a viral vector vaccine for prevention of COVID-19. AZD1222 has a sitelink_count of 54. The relationship is noted in the connected data as a related thing rather than explicitly as produced by SII.

### Affiliations and Relationships
- The company is connected to the biotechnology industry and is categorized under business activities.  
- Key people relationships link the corporate entity to Cyrus S. Poonawalla and Adar Poonawalla.  
- Product-development relationships connect SII to specific vaccine items (NVX‑CoV2373 and MMR vaccine) and note a relation to AZD1222.

### Structured Properties and Metadata
- Alias: SII.  
- Website: http://www.seruminstitute.com/.  
- Inception: 1966-01-01.  
- Entity sitelink_count: 26.  
- Wikipedia title: Serum Institute of India.  
- Wikidata description: Indian biotechnological company, vaccine manufacturer.

### References in Connected Data
- Business class entry referenced with sitelink_count 138.  
- Biotechnology industry entry referenced with sitelink_count 2.  
- Related item sitelink_counts: AZD1222 (54), NVX‑CoV2373 (25), MMR vaccine (41).  
- People sitelink_counts: Cyrus S. Poonawalla (12), Adar Poonawalla (11).  
- Location sitelink_counts: Pune (127), India (395).

### Summary of Relationships (compact)
- Country of origin: India.  
- Headquarters city: Pune.  
- Industry: Biotechnology.  
- Key leadership: Adar Poonawalla (CEO); Cyrus S. Poonawalla (key person).  
- Noted vaccine developments/associations: NVX‑CoV2373, MMR vaccine, and a relation to AZD1222.

(End of entry)

## References

1. Aligned ISNI and Ringgold identifiers for institutions
2. ROR release v1.19
3. GRID Release 2017-04-04